Venus Remedies Limited (VENUSREM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Venus Remedies Limited (VENUSREM) has a cash flow conversion efficiency ratio of 0.136x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs811.10 Million ≈ $8.77 Million USD) by net assets (Rs5.94 Billion ≈ $64.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Venus Remedies Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Venus Remedies Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VENUSREM liabilities breakdown for a breakdown of total debt and financial obligations.
Venus Remedies Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Venus Remedies Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Syrah Resources Ltd
AU:SYR
|
-0.089x |
|
Heidelberg Pharma AG
F:HPHA
|
-0.299x |
|
Multitude SE
LSE:0R4W
|
0.115x |
|
UBcare. Co. Ltd
KQ:032620
|
0.016x |
|
Laxmi Goldorna House Ltd
NSE:LGHL
|
-0.023x |
|
USBC, Inc.
NYSE MKT:USBC
|
-0.032x |
|
ANDREW PELLER LTD A
F:ANJ
|
0.013x |
|
Samick Thk
KO:004380
|
0.064x |
Annual Cash Flow Conversion Efficiency for Venus Remedies Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Venus Remedies Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Venus Remedies Limited stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs5.61 Billion ≈ $60.66 Million |
Rs909.20 Million ≈ $9.83 Million |
0.162x | +111.94% |
| 2024-03-31 | Rs4.88 Billion ≈ $52.73 Million |
Rs372.85 Million ≈ $4.03 Million |
0.076x | -3.87% |
| 2023-03-31 | Rs4.60 Billion ≈ $49.78 Million |
Rs366.20 Million ≈ $3.96 Million |
0.080x | -14.55% |
| 2022-03-31 | Rs4.40 Billion ≈ $47.63 Million |
Rs410.01 Million ≈ $4.43 Million |
0.093x | -71.90% |
| 2021-03-31 | Rs4.00 Billion ≈ $43.29 Million |
Rs1.33 Billion ≈ $14.34 Million |
0.331x | +39.12% |
| 2020-03-31 | Rs3.23 Billion ≈ $34.97 Million |
Rs770.10 Million ≈ $8.33 Million |
0.238x | +74.71% |
| 2019-03-31 | Rs3.33 Billion ≈ $35.96 Million |
Rs453.27 Million ≈ $4.90 Million |
0.136x | -4.09% |
| 2018-03-31 | Rs3.62 Billion ≈ $39.14 Million |
Rs514.36 Million ≈ $5.56 Million |
0.142x | -35.64% |
| 2017-03-31 | Rs4.52 Billion ≈ $48.84 Million |
Rs997.24 Million ≈ $10.78 Million |
0.221x | +106.13% |
| 2016-03-31 | Rs4.38 Billion ≈ $47.33 Million |
Rs468.81 Million ≈ $5.07 Million |
0.107x | -27.85% |
| 2015-03-31 | Rs4.57 Billion ≈ $49.39 Million |
Rs678.05 Million ≈ $7.33 Million |
0.148x | +30.18% |
| 2014-03-31 | Rs4.62 Billion ≈ $49.92 Million |
Rs526.46 Million ≈ $5.69 Million |
0.114x | -17.09% |
| 2013-03-31 | Rs3.79 Billion ≈ $41.00 Million |
Rs521.50 Million ≈ $5.64 Million |
0.138x | +1.44% |
| 2012-03-31 | Rs3.07 Billion ≈ $33.23 Million |
Rs416.70 Million ≈ $4.51 Million |
0.136x | -13.98% |
| 2011-03-31 | Rs2.37 Billion ≈ $25.62 Million |
Rs373.47 Million ≈ $4.04 Million |
0.158x | -14.83% |
| 2010-03-31 | Rs1.71 Billion ≈ $18.51 Million |
Rs316.83 Million ≈ $3.43 Million |
0.185x | +35.37% |
| 2009-03-31 | Rs1.39 Billion ≈ $14.99 Million |
Rs189.50 Million ≈ $2.05 Million |
0.137x | -36.02% |
| 2008-03-31 | Rs889.86 Million ≈ $9.62 Million |
Rs190.17 Million ≈ $2.06 Million |
0.214x | -50.89% |
| 2007-03-31 | Rs551.31 Million ≈ $5.96 Million |
Rs239.88 Million ≈ $2.59 Million |
0.435x | +58.20% |
| 2006-03-31 | Rs318.96 Million ≈ $3.45 Million |
Rs87.73 Million ≈ $948.76K |
0.275x | -- |
About Venus Remedies Limited
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more